One of the critical elements that have led to improved outcomes for intermediate-risk prostate cancer patients is the use of dose escalation (1e7). A meta-analysis of the seven randomized dose-escalated trials has demonstrated a biochemical control benefit for intermediate-risk patients with increasing biologically effective doses (BEDs) (5). Viani et al. found that a near linear benefit was evident with escalation of the radiation dose, and there was no sign that the dose effect had reached a plateau with further escalation of the radiation dose; these studies included BED of up to 175 Gy. In addition, Levegrun et al. (8) have used posttreatment biopsies to represent local control and suggested a TCP50 of 70.5 Gy (BED of 155 Gy) and near linear tumor control improvements with doses approaching 85 Gy (BED of 187 Gy). Current therapy for intermediate-risk patients with dose-escalated external beam radiation therapy (EBRT) plus androgen deprivation therapy (9, 10) result in 10-year actuarial biochemical failure rates of 20e25% and local failure rates of 15e25% (11, 12) . As seen in Table 1 (14) reported that intermediate-risk patients had a positive posttreatment biopsy rate of 14% when treated with a BED !150 Gy and only 5.3% biopsy positivity for BED O200 Gy. Importantly, residual disease post-EBRT has been shown to predict for both distant metastases and prostate cancererelated mortality (12) . Furthermore, a multiinstitutional study of intermediate-and high-risk patients demonstrated that a BED O220 Gy resulted in significantly improved freedom from biochemical failure, a dose not readily achieved by brachytherapy implant alone.
Beyond intraprostatic dose escalation, another important and recognized advantage of supplemental EBRT is the ability to cover extraprostatic disease for extracapsular extension (ECE), seminal vesicle invasion (SVI), and even lymph node involvement (Table 2 ). Based on original Partin data using the Roach formula, even low-risk patients can have O40% risk of having ECE at time of radical prostatectomy (15) . To complicate this issue further, standard hematoxylin and eosin (H & E) staining has been shown to underestimate the presence of ECE, which has been confirmed by molecular studies (16) . Multiple series have demonstrated that ECE commonly extends up to 5 mm radially from the prostate, with maximum tumor extension documented $10 mm (17, 18) . Dosimetric data from Merrick et al. (19) have demonstrated that the distance measured radially from the prostate is encompassed by the 100% isodose line at a distance of $3 mm from the prostate only 86% of the time and !70% is encompassed when at a distance $5 mm from the prostate. Even when analyzing coverage by the 75% isodose line,~7% of the coverage on average was not encompassed $5 mm from the prostate (19) . At the edge of the target volume, the dose decreases up to~20 Gy/mm; thus, if the margin is 3 mm at a point, but ECE extends to 5 mm, a 144-Gy implant may decrease to 100 Gy in the region of ECE. This would represent substantial underdosage of disease and would have the biologic equivalence of delivering 50.4 Gy using EBRT as monotherapy, a grossly insufficient dose to treat ECE. This concern of monotherapy potentially representing underdosage of disease is clearly illustrated in Fig. 1 .
Despite excellent clinical outcomes with combination therapy, one must ask if we are simply shifting the therapeutic ratio by increasing tumor control with a concomitant increased risk for toxicity, or if we are actually improving the therapeutic ratio. Multiple prospective trials have evaluated the safety of combination therapy. Two randomized Phase 3 trials found slightly differing results regarding the toxicity of combination EBRT and brachytherapy (6, 7, 20) . Hoskin et al. (7) reported that combination therapy resulted in similar rates of genitourinary (GU) toxicity but, interestingly, demonstrated decreased rates of acute rectal toxicity with combination therapy. Sathya et al. (6) reported a nonsignificant ( p 5 0.09) increase in late GU toxicity with combination therapy over non-doseeescalated EBRT, and no difference in late GI toxicity. Radiation Therapy Oncology Group 0019 was a Phase II multi-institutional trial that used combination EBRT with low dose rate (LDR) brachytherapy and reported that of 138 patients, 4 (2.9%) experienced Grade 3 gastrointestinal (GI) toxicity and 15 (8.3%) experienced Grade $3 GU toxicity (21) . Notably, this trial required a four-field box technique with margins up to 2 cm on the clinical target volume. Utilization of intensity-modulated radiation therapy, and even image-guided radiotherapy with fiducial marker placement, likely would have reduced the toxicity further. The Cancer and Leukemia Group B 99809 reported their long-term Phase II results from combination brachytherapy and EBRT with the addition of androgen deprivation therapy for intermediate-risk patients (22) . With a median followup of over 6 years, the authors reported remarkable low rates of late Grade 3 toxicity (3% [95% confidence interval, 0e8%]). As there continue to be advances in imaging technology, there is a potential for additional improvements in intraoperative treatment planning and delivery to further improve outcomes.
It would be an overstatement to imply that all intermediate-risk patients require combination therapy. ''Intermediate risk'' comprises a heterogeneous group of patients with vastly different risks for failure (23) . The current National Comprehensive Cancer Network risk grouping does not take into account important prognostic features such as percent positive biopsy cores (9), primary Gleason pattern (24) , or prostate-specific antigen kinetics (25) 
